- Home
- HMST vs ADCT Comparison
HMST vs ADCT Comparison
Compare HMST & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- ADCT
- Stock Information
- Founded
- HMST 1921
- ADCT 2011
- Country
- HMST United States
- ADCT Switzerland
- Employees
- HMST N/A
- ADCT N/A
- Industry
- HMST Major Banks
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- ADCT Health Care
- Exchange
- HMST Nasdaq
- ADCT Nasdaq
- Market Cap
- HMST 246.0M
- ADCT 241.0M
- IPO Year
- HMST 2012
- ADCT 2020
- Fundamental
- Price
- HMST $12.42
- ADCT $2.78
- Analyst Decision
- HMST Hold
- ADCT Strong Buy
- Analyst Count
- HMST 3
- ADCT 6
- Target Price
- HMST $14.17
- ADCT $7.80
- AVG Volume (30 Days)
- HMST 63.9K
- ADCT 917.3K
- Earning Date
- HMST 07-28-2025
- ADCT 08-05-2025
- Dividend Yield
- HMST N/A
- ADCT N/A
- EPS Growth
- HMST N/A
- ADCT N/A
- EPS
- HMST N/A
- ADCT N/A
- Revenue
- HMST $78,454,000.00
- ADCT $75,817,000.00
- Revenue This Year
- HMST $161.80
- ADCT $10.65
- Revenue Next Year
- HMST $8.90
- ADCT $15.05
- P/E Ratio
- HMST N/A
- ADCT N/A
- Revenue Growth
- HMST N/A
- ADCT 10.49
- 52 Week Low
- HMST $8.41
- ADCT $1.05
- 52 Week High
- HMST $16.10
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- HMST 50.71
- ADCT 47.62
- Support Level
- HMST $12.05
- ADCT $3.21
- Resistance Level
- HMST $12.51
- ADCT $3.97
- Average True Range (ATR)
- HMST 0.33
- ADCT 0.38
- MACD
- HMST -0.12
- ADCT -0.12
- Stochastic Oscillator
- HMST 28.91
- ADCT 3.43
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).